A Phase 3, Randomized, Double-Blind, Parallel-Group, Pacebo-controlled study to determine the efficacy and safety of Milvexian, an Oral Factor Xia Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack.
If you would like additional information regarding this trial, please contact researchopportunities@prairieresearch.com